Compare Quest Diagnostics Inc (DGX) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while KraneShares Electric Vehicles and Future Mobility trades at $27.86 (market cap $72.36M). The key difference: Quest Diagnostics Inc is far larger — about 352.1× KraneShares Electric Vehicles and Future Mobility's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and KraneShares Electric Vehicles and Future Mobility for 46 Days on average.
| DGX | KARS | |
|---|---|---|
Market Cap | $25.48B | $72.36M |
Volume | 941,866 | 5,034 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $38.01 |
52-Week Low | $173.49 | $27.25 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
KARS trades at $27.86, up 0.25% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 54.12 and 45.15, while ADX indicates mixed trend strength. Support and resistance cluster around $28-$29 levels, suggesting potential consolidation. Recent news highlights mixed EV market trends with US sales lagging while global demand grows.
The outlook remains cautious given bearish technical signals and mixed EV market dynamics. Investment opportunity exists in global EV growth trends, but risks include US market headwinds and regulatory uncertainty. Stock performance may depend on company-specific execution amid evolving industry conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
